Oliveira João P, Nowak Albina, Barbey Frédéric, Torres Márcia, Nunes José P, Teixeira-E-Costa Fernando, Carvalho Fernanda, Sampaio Susana, Tavares Isabel, Pereira Odete, Soares Ana L, Carmona Cátia, Cardoso Maria-Teresa, Jurca-Simina Iulia E, Spada Marco, Ferreira Susana, Germain Dominique P
Service of Medical Genetics, São João University Hospital Center, 4200-319, Porto, Portugal; Unit of Genetics, Department of Pathology, Faculty of Medicine, University of Porto, 4200-319, Porto, Portugal; Institute for Research and Innovation in Health [Instituto de Investigação e Inovação em Saúde] - I3S, University of Porto, 4150-180, Porto, Portugal.
Department of Endocrinology and Clinical Nutrition, University of Zurich, 8091, Zürich, Switzerland.
Eur J Med Genet. 2020 Feb;63(2):103703. doi: 10.1016/j.ejmg.2019.103703. Epub 2019 Jun 11.
BACKGROUND, AIMS AND METHODS: The α-galactosidase gene (GLA) c.337T>C/p.Phe113Leu variant was originally described in patients with late-onset cardiac forms of Fabry disease (FD), who had residual α-galactosidase activity. It has since emerged as the most commonly reported GLA variant in Portuguese subjects diagnosed with FD but is also prevalent in the Italian population, where two boys carrying the GLA Leu113 allele were identified in a large-scale newborn screening program, the variant allele segregating in both cases with the same surrounding haplotype. To further delineate the genotype-phenotype correlations of this GLA variant, we have reviewed the natural history and clinical phenotypes of 11 symptomatic Portuguese males, from 10 unrelated families originating from several different areas in mainland Portugal and Madeira Island, who were diagnosed with FD associated with the GLA Leu113 allele in a diversity of clinical and screening settings. Nine of the patients were the probands of their respective families. To test whether the GLA Leu113 allele inherited by the 10 Portuguese and the two Italian families resulted from independent mutational events, we have additionally performed a haplotype analysis with 5 highly polymorphic, closely linked microsatellite markers surrounding the GLA gene.
Hemizygosity for the GLA Leu113 variant allele is associated with a late-onset form of FD, invariably presenting with severe cardiac involvement. Clinically relevant cerebrovascular and kidney involvement may also occur in some patients but the pathogenic relationship between the incomplete α-galactosidase deficiency and the risks of stroke and of chronic kidney disease is not straightforward. The observation that the Leu113 allele segregated within the same GLA microsatellite haplotype in both the Portuguese and Italian families suggests its inheritance from a common ancestor.
背景、目的和方法:α-半乳糖苷酶基因(GLA)c.337T>C/p.Phe113Leu变异最初在晚发型心脏型法布里病(FD)患者中被描述,这些患者具有残余的α-半乳糖苷酶活性。此后,它已成为葡萄牙被诊断为FD的受试者中最常报告的GLA变异,但在意大利人群中也很普遍,在一项大规模新生儿筛查项目中,发现两名携带GLA Leu113等位基因的男孩,该变异等位基因在两例中均与相同的周围单倍型分离。为了进一步描述这种GLA变异的基因型-表型相关性,我们回顾了11名有症状的葡萄牙男性的自然病史和临床表型,这些男性来自葡萄牙大陆和马德拉岛几个不同地区的10个无关家庭,他们在各种临床和筛查环境中被诊断为与GLA Leu113等位基因相关联的FD。其中9名患者是各自家庭的先证者。为了测试10个葡萄牙家庭和2个意大利家庭所遗传的GLA Leu113等位基因是否源于独立的突变事件,我们还使用围绕GLA基因的5个高度多态性、紧密连锁的微卫星标记进行了单倍型分析。
GLA Leu113变异等位基因的半合子状态与晚发型FD相关,总是表现为严重的心脏受累。一些患者也可能出现临床相关的脑血管和肾脏受累,但不完全α-半乳糖苷酶缺乏与中风和慢性肾病风险之间的致病关系并不直接。葡萄牙和意大利家庭中Leu113等位基因在相同的GLA微卫星单倍型内分离的观察结果表明,它是从一个共同祖先遗传而来的。